Results 121 to 130 of about 11,219 (248)
Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.This retrospective study evaluated 422 dogs with neurological disorders among 9131 canine referrals over 8.5 years in northeastern Iran. Infectious diseases, particularly canine distemper (33.2%), were the leading cause, followed by trauma and idiopathic conditions. The prosencephalon was the most frequently affected anatomical region.
Ali Behrouzian +2 more
wiley +1 more source
Вивчення депресивних порушень у хворих на міастенію [PDF]
, 2018 Вивчено депресивні прояви у 96 хворих на міастенію. В результаті роботи встановлено, що частота розвитку депресивних порушень у хворих на міастенію збільшується з тривалістю перебігу хвороби.
Кальбус, О.І.
core
Evaluating inebilizumab in the treatment of generalized myasthenia gravis
ImmunotherapyMyasthenia gravis (MG) is the most common neuromuscular junction disorder. Despite the recent advances in the field, there are still unmet needs. Novel treatments based on new mechanisms of action are now available, including complement inhibitors, neonatal FcRn inhibitors and more recently, B cell-targeted therapies.
openaire +2 more sources
Veterinary Record Case Reports, Volume 14, Issue 2, May 2026.Summary This case report describes a 10‐year‐old, male, neutered labrador retriever that was presented with acute non‐ambulatory tetraparesis, later diagnosed with an ectopic insulinoma and paraneoplastic polyneuropathy. Clinical evaluation revealed severe hypoglycaemia, generalised neuromuscular signs and electromyography findings were consistent with
Laryssa Straub +3 more
wiley +1 more source
Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
The Journal of Dermatology, Volume 53, Issue 5, Page 758-773, May 2026.ABSTRACT Vitiligo is a chronic autoimmune depigmenting disease characterized by loss of pigment in the skin, hair, or both. As treatment options evolve, particularly with the emergence of oral Janus kinase inhibitors and dual Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, it is essential to assess ...
Kennedy Cook +11 more
wiley +1 more source
Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections
Frontiers in ImmunologyHighly active myasthenia gravis refers to a subset of refractory patients who exhibit recurrent exacerbations and crises. Eculizumab, a complement C5 inhibitor, has shown its efficacy and safety for patients with anti-acetylcholine receptor antibody ...
Yufei Deng +8 more
doaj +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Seronegative myasthenia gravis in Hong Kong Chinese [PDF]
, 2003 published_or_final_versio
Chan, KH +6 more
core
Clinical Otolaryngology, Volume 51, Issue 3, Page 418-425, May 2026.ABSTRACT Objective To assess if surgery for Obstructive Sleep Apnea Disorder (OSAD) is safe for infants and toddlers. Methods Retrospective cohort study of paediatric patients undergoing OSA surgery; partial or complete tonsillectomy with adenoidectomy, tonsillectomy without adenoidectomy and adenoidectomy.
Daniel Levi +8 more
wiley +1 more source
Myasthenia Gravis in Pregnancy: A Case Report
Case Reports in Obstetrics and Gynecology, 2012 Objective. To present a case of maternal myasthenia gravis in pregnancy and give a systematic review of the literature. Case. We report the case of a 38-year-old parturient with a life-threatening complication of immune-mediated myasthenia gravis shortly
Sebastian Berlit +4 more
doaj +1 more source